Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final deal structure.
Key takeaways (Nov. 10)
- Deal locked with Pfizer at up to $86.25 per share: $65.60 cash at closing plus up to $20.65 in contingent value rights (CVRs), matching the headline value of Novo’s last proposal but with a simpler path to close, according to company disclosures.
- Today’s market move: MTSR traded near $70 intraday (≈‑12% to ‑16% on the session), reflecting disappointment from investors who had bet on a richer bidding outcome.
- Novo exits: Novo Nordisk said it dropped its bid; its shares rose in Copenhagen trading today as the auction ended.
- Fresh 8‑K spells out the fine print: The filing raises the termination fee and details CVR milestones tied to Metsera’s monthly GLP‑1 and amylin programs; it also removes a prior $1.5B development‑spend covenant.
What changed today
- Premarket selloff: Reuters reported MTSR down more than 15% after Metsera accepted Pfizer’s sweetened offer and Novo exited. The final headline value is “up to $10B.”
- Press‑release confirmation: Metsera reiterated the board’s unanimous recommendation for the amended Pfizer merger and said it expects to close promptly after the Nov. 13 shareholder meeting, citing U.S. FTC antitrust concerns around Novo’s proposal.
The revised terms, line by line (from today’s 8‑K)
Metsera’s Form 8‑K filed this morning lays out material changes versus the September agreement:
- Cash consideration lifted from $47.50 to $65.60 per share.
- CVR cap trimmed from $22.50 to $20.65 per share, split across three milestones:
- $4.60 on first Phase 3 start for the monthly GLP‑1 + amylin combo (MET‑097i + MET‑233i) by Dec. 31, 2027.
- $6.40 on FDA approval of monthly MET‑097i by Dec. 31, 2029.
- $9.65 on FDA approval of the combo by Dec. 31, 2031.
- Termination fee increased to $265M if Metsera walks for a superior offer.
- Pfizer must use “commercially reasonable efforts” to achieve each milestone, while the prior requirement to spend at least $1.5B on development of the CVR products is removed.
- Mutual releases: at closing, the parties (and certain shareholders) agree to mutually release claims tied to the earlier merger process and actions related to Novo.
Why Novo bowed out — and the FTC’s role
Metsera’s Nov. 7 release said the board received a call from the FTC flagging U.S. antitrust risks in Novo’s proposed structure, which included a large up‑front dividend. The board deemed Novo’s path “unacceptably high” legal and regulatory risk and reaffirmed Pfizer. Reuters’ Breakingviews likewise notes the FTC’s intervention and summarizes the agreed price split ($65.60 cash + CVR to $86.25).
Market context and investor read‑through
- Bidding war ends: With Novo stepping aside, Monday’s financial press spotlighted Metsera as a major mover to the downside, while Pfizer shares were modestly higher.
- Strategic fit: Analysts say the deal gives Pfizer a credible re‑entry into the booming obesity market, though Metsera’s products are years from commercialization.
What Metsera is bringing to Pfizer
Metsera’s pipeline targets less‑frequent dosing and combo therapy in obesity:
- MET‑097i: fully biased GLP‑1 with potential once‑monthly dosing (mid‑stage development).
- MET‑233i: amylin analog aimed at monthly dosing and co‑formulation with MET‑097i.
These candidates underpin the CVR milestones and the strategic rationale behind Pfizer’s pursuit.
What’s next (this week)
- Shareholder vote: Special meeting on Nov. 13; parties expect to close promptly afterward subject to conditions.
- Regulatory filings & integration prep: Watch for closing updates and any post‑vote disclosures as Pfizer moves to integrate Metsera’s clinical programs.
Sources & further reading
- Metsera 8‑K (filed Nov. 10, 2025) detailing revised terms and CVR milestones.
- Metsera press release (Nov. 7): board reaffirms Pfizer deal; notes FTC outreach; Nov. 13 vote timing.
- Reuters (Nov. 10): MTSR falls after accepting Pfizer’s sweetened offer; Novo exits.
- Reuters Breakingviews (Nov. 10): Price split and FTC intervention context.
- Barron’s (Nov. 10): Metsera among Monday’s movers as auction ends.
Editorial note: This article is for informational purposes only and does not constitute investment advice.
